Gin-Chung Liu1,2, Yun-Ming Wang3, Ming-Hong Chen3, Kun-Liang Lin3, Chiao-Yun Chen1,4
1Department of Medical Imaging, Kaohsiung Medical University Hospital, Kaohsiung, Taiwan; 2Department of Radiology, Kaohsiung Medical University, Kaohsiung, Taiwan; 3Biological Science & Technology, National Chiao Tung University, Hsin Chu, Taiwan; 4Department of Radiology, Kaohsiung Medical University, Taiwan
Technological limitations of imaging modality often hold back diagnosis and therapy of cancer. It is widely accepted that early diagnosis may lead to cure or at least offer extended life to the cancer patient. Recent studies have demonstrated that Erbitux can be potentially employed for targeted drug delivery to tumor site. Herein, we report EGFR specific multimodal imaging agents, MnFe2O4-Erubitux-CyTE777 nanoparticles. MR imaging studies were performed with a 3.0 T MR imager and body fluorescent images were carried out by IVIS spectrum imaging system. Thus, the multimodal nanoparticles could be potentially used as contrast agents for molecular MR imaging.